Common Stock
- Symbol
- ETON
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Eton Pharmaceuticals, Inc.
ETONNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms.…
Registered securities in this filing
ETON PHARMACEUTICALS, INC. · 8-K · Filed 2026-08-04
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms. Radosavljevic previously held the position of Executive Vice President, Operations at the Company overseeing quality, product development, regulatory, supply chain and information systems for more than the past five years. Ms. Radosavljevic has been with the Company since 2017.
Ms. Radosavljevic's compensation package includes an annual base salary of $520,800 and an annual discretionary incentive bonus at a total annual target amount of 50% of base salary, based on the achievement of corporate and/or individual performance targets to be determined and approved by the Board of Directors.